2024
Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G, Deng Y, Ross J, Mickelson M, McCoy R. Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal Of The American Society Of Nephrology 2024 DOI: 10.2215/cjn.0000000587.Peer-Reviewed Original ResearchSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2Dipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Dipeptidyl peptidase-4Receptor agonistsPrimary composite outcomeKidney replacement therapyChronic kidney diseaseComposite outcomeSecondary composite outcomeType 2 diabetesGLP-1 receptor agonist therapyCVD riskCardiovascular diseaseModerate CVD riskPrescribed glucose-lowering agentsBaseline CVD riskHigh-risk patientsAssociated with risk reductionCKD stage 3Retrospective observational studyGlucose-lowering agentsModerate cardiovascular risk
2018
Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes
McCoy RG, Herrin J, Lipska KJ, Shah ND. Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. Journal Of Diabetes And Its Complications 2018, 32: 693-701. PMID: 29751961, PMCID: PMC6015781, DOI: 10.1016/j.jdiacomp.2018.04.007.Peer-Reviewed Original ResearchConceptsRecurrent hyperglycemiaRecurrent hypoglycemiaNew glucose-lowering medicationsPost-discharge managementGlucose-lowering medicationsHigh-risk patientsOptumLabs Data WarehouseHypoglycemia hospitalizationIndex dischargeOlder patientsRisk patientsUnrelated causesSevere hypoglycemiaRecurrent hospitalizationsNational cohortEarly recognitionPrincipal diagnosisRisk factorsRetrospective analysisHyperglycemiaHypoglycemiaPatientsReadmissionU.S. adultsHospitalizationEffect of Hospital Readmission Reduction on Patients at Low, Medium, and High Risk of Readmission in the Medicare Population
Blecker S, Herrin J, Kwon JY, Grady JN, Jones S, Horwitz LI. Effect of Hospital Readmission Reduction on Patients at Low, Medium, and High Risk of Readmission in the Medicare Population. Journal Of Hospital Medicine 2018, 13: 537-543. PMID: 29455229, PMCID: PMC6063766, DOI: 10.12788/jhm.2936.Peer-Reviewed Original Research
2016
Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program
Jenq GY, Doyle MM, Belton BM, Herrin J, Horwitz LI. Quasi-Experimental Evaluation of the Effectiveness of a Large-Scale Readmission Reduction Program. JAMA Internal Medicine 2016, 176: 681. PMID: 27065180, DOI: 10.1001/jamainternmed.2016.0833.Peer-Reviewed Original ResearchConceptsDischarge patientsReadmissions Reduction ProgramControl populationReadmission ratesIntervention periodSame-hospital readmission ratesUrban academic medical centerTarget populationAdjusted readmission ratesOdds of readmissionHigh-risk patientsZip codesAdjusted admission ratesInterrupted time series analysisAcademic medical centerQuasi-experimental evaluationLogistic regression modelsReduction programsDischarge dispositionReadmission reduction effortsComparative interrupted time series analysisMedication reconciliationService patientsMean ageTransitional care